These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38658340)
1. Treatment of cryptogenic new-onset refractory status epilepticus (C-NORSE) with tocilizumab: A case report. Nakamura Y; Ueda M; Kodama S; Kimura T; Shirota Y; Hamada M; Ishiura H; Iizuka T; Toda T Intern Med; 2024 Apr; ():. PubMed ID: 38658340 [TBL] [Abstract][Full Text] [Related]
2. Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment. Wadayama T; Shimizu M; Yata T; Ishikura T; Kajiyama Y; Hirozawa D; Okuno T; Mochizuki H J Neuroimmunol; 2022 Feb; 363():577789. PubMed ID: 34973472 [TBL] [Abstract][Full Text] [Related]
3. Second-line immunotherapy in new onset refractory status epilepticus. Hanin A; Muscal E; Hirsch LJ Epilepsia; 2024 May; 65(5):1203-1223. PubMed ID: 38430119 [TBL] [Abstract][Full Text] [Related]
4. A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome. Sheikh Z; Hirsch LJ Front Neurol; 2023; 14():1150496. PubMed ID: 37251223 [TBL] [Abstract][Full Text] [Related]
5. A favorable outcome of intensive immunotherapies for new-onset refractory status epilepticus (NORSE). Kodama S; Arai N; Hagiwara A; Kimura A; Takeuchi S J Intensive Care; 2018; 6():43. PubMed ID: 30083346 [TBL] [Abstract][Full Text] [Related]
6. Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab. Donnelly JP; Kasatwar N; Hafeez S; Seifi A; Gilbert A; Barthol C; Small C; Ákos Szabó C Epilepsy Behav Rep; 2021; 15():100431. PubMed ID: 33748736 [TBL] [Abstract][Full Text] [Related]
7. NORSE seasonality may vary geographically in adults. Bolle AE; Gaist T; Kuljis AME; Blaabjerg M; Beier CP Epilepsia Open; 2024 Jun; 9(3):1088-1095. PubMed ID: 38635008 [TBL] [Abstract][Full Text] [Related]
8. The seasonality of new-onset refractory status epilepticus (NORSE). Gopaul MT; Hanin A; Cespedes J; Pulluru Y; Kazazian K; van Baalen A; Gofton TE; Gaspard N; Hirsch LJ Epilepsia; 2023 Jun; 64(6):e112-e117. PubMed ID: 37013696 [TBL] [Abstract][Full Text] [Related]
9. [A case of cryptogenic new-onset refractory status epilepticus (NORSE) in which cerebrospinal fluid IL-6 was elevated with increased seizure frequency early in the disease: a case report]. Nakada R; Terasawa Y; Sato T; Takatsu H; Kaito N; Iguchi Y Rinsho Shinkeigaku; 2023 Dec; 63(12):843-846. PubMed ID: 37989289 [TBL] [Abstract][Full Text] [Related]
10. Neuropathology of New-Onset Refractory Status Epilepticus (NORSE). Hanin A; Cespedes J; Huttner A; Strelnikov D; Gopaul M; DiStasio M; Vezzani A; Hirsch LJ; Aronica E J Neurol; 2023 Aug; 270(8):3688-3702. PubMed ID: 37079033 [TBL] [Abstract][Full Text] [Related]
12. The etiology and mortality of new-onset refractory status epilepticus (NORSE) in adults: A systematic review and meta-analysis. Tharmaraja T; Ho JSY; Neligan A; Rajakulendran S Epilepsia; 2023 May; 64(5):1113-1124. PubMed ID: 36727541 [TBL] [Abstract][Full Text] [Related]
13. Blood-brain barrier damage and new onset refractory status epilepticus: An exploratory study using dynamic contrast-enhanced magnetic resonance imaging. Li H; Liu X; Wang R; Lu A; Ma Z; Wu S; Lu H; Du Y; Deng K; Wang L; Yuan F Epilepsia; 2023 Jun; 64(6):1594-1604. PubMed ID: 36892496 [TBL] [Abstract][Full Text] [Related]
14. Histopathology of new-onset refractory status epilepticus (NORSE) in adults. Suchdev K; Kupsky WJ; Mittal S; Shah AK Seizure; 2021 Dec; 93():95-101. PubMed ID: 34740145 [TBL] [Abstract][Full Text] [Related]
15. Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort). Sculier C; Barcia Aguilar C; Gaspard N; Gaínza-Lein M; Sánchez Fernández I; Amengual-Gual M; Anderson A; Arya R; Burrows BT; Brenton JN; Carpenter JL; Chapman KE; Clark J; Gaillard WD; Glauser TA; Goldstein JL; Goodkin HP; Gorman M; Lai YC; McDonough TL; Mikati MA; Nayak A; Peariso K; Riviello J; Rusie A; Sperberg K; Stredny CM; Tasker RC; Tchapyjnikov D; Vasquez A; Wainwright MS; Wilfong AA; Williams K; Loddenkemper T; Epilepsia; 2021 Jul; 62(7):1629-1642. PubMed ID: 34091885 [TBL] [Abstract][Full Text] [Related]
16. Understanding new-onset refractory status epilepticus from an immunological point of view. Shin YW Encephalitis; 2021 Jul; 1(3):61-67. PubMed ID: 37469848 [TBL] [Abstract][Full Text] [Related]
17. Severe, Refractory Seizures: New-Onset Refractory Status Epilepticus and Febrile Infection-Related Epilepsy Syndrome. Carson R; Stredny CM Med Clin North Am; 2024 Jan; 108(1):201-213. PubMed ID: 37951651 [TBL] [Abstract][Full Text] [Related]
18. The Increased Interleukin-6 Levels Can Be an Early Diagnostic Marker for New-Onset Refractory Status Epilepticus. Kwack DW; Kim DW J Epilepsy Res; 2022 Dec; 12(2):78-81. PubMed ID: 36685741 [TBL] [Abstract][Full Text] [Related]
19. Cryptogenic New Onset Refractory Status Epilepticus (NORSE) in adults-Infectious or not? Costello DJ; Kilbride RD; Cole AJ J Neurol Sci; 2009 Feb; 277(1-2):26-31. PubMed ID: 19013586 [TBL] [Abstract][Full Text] [Related]